https://www.fortunebusinessinsights.com/stomach-gastric-cancer-treatment-market-102094
https://www.fortunebusinessinsights.com/stomach-gastric-cancer-treatment-market-102094
The global stomach cancer treatment market was valued at USD 2.61 billion in 2018 and is expected to
grow at a CAGR of 16.0%, reaching USD 20.92 billion by 2032. In 2018, the Asia Pacific region led the
market, accounting for a 38.7% share.
The stomach cancer treatment market focuses on providing medical solutions for one of the most
common and aggressive forms of cancer worldwide. As the number of cases continues to rise, especially
in regions with high-risk factors like poor diet and Helicobacter pylori infection, the demand for effective
treatment options is increasing. This market includes a range of therapies such as chemotherapy,
targeted therapy, immunotherapy, and radiation therapy. Advances in personalized medicine and early
detection techniques are helping improve treatment outcomes. With ongoing research and the
introduction of new drugs, the stomach cancer treatment market is gradually evolving to offer more
precise and less toxic treatment options for patients.
Tariff Impact Analysis for Stomach Cancer Treatment Market:
https://www.fortunebusinessinsights.com/stomach-gastric-cancer-treatment-market-102094
List Of Key Companies Covered In Stomach Cancer Treatment Market:
•
Ipsen Pharma
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Bayer AG
• Celltrion Inc.s
• TAIHO PHARMACEUTICAL CO., LTD.
•
Jiangsu Hengrui Medicine Co., Ltd.
Market Drives:
Stomach cancer is becoming a leading cause of death worldwide. According to the WHO, the number of
new stomach cancer cases is expected to rise from 1.03 million in 2018 to 1.24 million by 2025. This
growing incidence of gastric carcinoma is likely to drive increased demand for stomach cancer
treatments during the forecast period, positioning it as a key trend in the market. Additionally, the
growing use of advanced diagnostic tools for early detection is expanding the patient population. This
trend is expected to further contribute to the growth of the stomach cancer drugs market in the coming
years.
Market Segmentation:
The stomach cancer treatment market is segmented by drug type, with PD-1 inhibitors expected to
dominate due to increased research and approvals, such as Keytruda’s FDA approval in 2017. The HER2
antagonists segment is projected to grow due to government support for biosimilars and pipeline
candidates. VEGFR antagonists are also set to expand, driven by the rising prevalence of stomach
cancer. The "others" segment, which includes chemotherapy drugs like Lonsurf, fluorouracil, and
capecitabine, remains strong, especially in developing countries. By disease indication, gastric
sales@fortunebusinessinsights.com
adenocarcinoma is expected to dominate, driven by rising prevalence and the adoption of targeted
therapies. The parenteral route of administration is likely to register the highest CAGR, thanks to
favorable reimbursement and more intravenous drugs. Hospital pharmacies are anticipated to benefit
from government support, while retail and online pharmacies will see growth due to increasing
treatment centers and online drug sales.
Regional Analysis:
Asia Pacific, with a revenue of USD 1.01 billion in 2018, holds the largest share of the stomach cancer
treatment market, driven by rising gastric cancer cases in Japan, China, and India, and the adoption of
PD-1 inhibitors. The region is expected to maintain dominance throughout the forecast period. North
America’s market growth is fueled by strategic collaborations, increased R&D spending, and the rising
incidence of stomach cancer, with 27,510 cases estimated in the U.S. in 2019. Europe is set to
experience growth due to new product launches, favorable health reimbursement, and collaborations
like Boehringer Ingelheim's partnership with PureTech Health. In Latin America and the Middle East &
Africa, improving healthcare infrastructure and unmet patient needs are expected to drive demand for
gastric carcinoma treatments.
Key Industry Developments:
•
In May 2021, Bold Therapeutics received Orphan Drug Designation (ODD) for BOLD-100, a first-
in-class ruthenium-based small molecule therapeutic, for the treatment of gastric cancer.
•
In April 2021, Bristol Myers Squibb gained U.S. FDA approval for Opdivo (nivolumab) as the first
immunotherapy for the first-line treatment of gastric cancer.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.: +1 424 253 0390
U.K.: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com